Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.60 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.54 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.51 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL16935555 | 0.92 | BRAF (0.53) | BRAFPDPK1GDAMAP3K5CDK1 | |
| Guanine SCHEMBL26102381 | 0.87 | PNP (0.63) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL6509992 | 0.82 | XDH (0.45) | BRAF | |
| SCHEMBL164700 | 0.81 | XDH (0.65) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL3396378 | 0.80 | PDPK1 (0.61) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL2938906 | 0.78 | PDPK1 (0.59) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL29672206 | 0.78 | PDPK1 (0.59) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL16147021 | 0.77 | CDK1 (0.63) | BRAFPDPK1GDAMAP3K5CDK1 | |
| SCHEMBL1808629 | 0.77 | ADORA3 (0.42) | BRAFCDK1CDK2CCNB1CCNA2 | |
| Methylguanine SCHEMBL7217780 | 0.77 | BRAF (0.56) | BRAFMAP3K5CDK1CDK2CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 757 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11371094-B2 | Systems and methods for nucleic acid processing using degenerate nucleotides | 10X GENOMICS, INC. (US) | 2022-06-28 | — | — | US | claimed |
| CN-108350499-B | Convertible marking compositions, methods, and processes incorporating same | 10X基因组学有限公司 | 2022-05-13 | — | — | CN | claimed |
| US-20210285044-A1 | SYSTEMS AND METHODS FOR NUCLEIC ACID PROCESSING USING DEGENERATE NUCLEOTIDES | 10X GENOMICS, INC. | 2021-09-16 | — | — | US | claimed |
| EP-3377657-B1 | TRANSFORMABLE TAGGING METHODS | 10X GENOMICS INC (US) | 2020-11-11 | — | — | EP | claimed |
| EP-3377657-A1 | TRANSFORMABLE TAGGING COMPOSITIONS, METHODS, AND PROCESSES INCORPORATING SAME | 10X Genomics, Inc. (US) | 2018-09-26 | — | — | EP | claimed |
| US-20170145476-A1 | TRANSFORMABLE TAGGING COMPOSITIONS, METHODS, AND PROCESSES INCORPORATING SAME | 10X GENOMICS, INC. | 2017-05-25 | — | — | US | claimed |
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | claimed |
| EP-1802772-A4 | METHODS FOR LONG-RANGE SEQUENCE ANALYSIS OF NUCLEIC ACIDS | SEQUENOM INC (US) | 2008-12-31 | — | — | EP | claimed |
| EP-1802772-A2 | METHODS FOR LONG-RANGE SEQUENCE ANALYSIS OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 2007-07-04 | — | — | EP | claimed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| EP-1011608-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | Epigenesis Pharmaceuticals, Inc. (US) | 2000-06-28 | — | — | EP | claimed |
| US-6074818-A | GENERATING PROFILES OF INCREASED FIDELITY USING OLIGONUCLEOTIDE PRIMERS WITH HAIRPIN STRUCTURES | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2000-06-13 | — | — | US | claimed |
| US-6043059-A | PERFORMING SERIES OF REACTIONS INVOLVING HYBRIDIZING PRIMER TO TARGET AND EFFECTING CHAIN EXTENSION/CHAIN TERMINATION; USING PRIMER FROM PRESYNTHESIZED SET HAVING RAISED ANNEALING TEMPERATURE AND/OR IMPROVED ANNEALING PROPERTIES | AMERSHAM PHARMACIA BIOTECH UK (GB) | 2000-03-28 | — | — | US | claimed |
| WO-1999063938-A9 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS INC (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999063938-A2 | COMPOSITION AND METHOD FOR PREVENTION AND TREATMENT OF CARDIOPULMONARY AND RENAL FAILURE OR DAMAGE ASSOCIATED WITH ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR BROUGHT ABOUT BY ADMINISTRATION OF CERTAIN DRUGS | EPIGENESIS PHARMACEUTICALS, INC. (US) | 1999-12-16 | — | — | WO | claimed |
| US-5962221-A | Oligonucleotide constructs and methods for the generation of sequence signatures from nucleic acids | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 1999-10-05 | — | — | US | claimed |
| WO-1999013886-A1 | MULTIPLE TARGET HYBRIDIZING NUCLEIC ACIDS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS | EAST CAROLINA UNIVERSITY (US) | 1999-03-25 | — | — | WO | claimed |
| EP-0837950-A1 | PRIMER WALKING CYCLE SEQUENCING | Amersham Life Science (GB) | 1998-04-29 | — | — | EP | claimed |
| WO-1997001645-A1 | PRIMER WALKING CYCLE SEQUENCING | AMERSHAM LIFE SCIENCE (GB) | 1997-01-16 | — | — | WO | claimed |
| WO-1993005175-A1 | IMPROVEMENTS IN OLIGONUCLEOTIDE PRIMERS AND PROBES | MEDICAL RESEARCH COUNCIL (GB) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | BRAF 2862/4885PDPK1 2311/4885GDA 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.